Study record
MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway
Hu BT, Chen WZ · Eur Rev Med Pharmacol Sci · 2018
CellsMOTS-c administeredEvidence tier D
What this study reported
In rat BMSCs, MOTS-c treatment was reported to stimulate calcified nodule formation and upregulate TGF-β/Smad pathway genes. The increase in osteogenesis was reversed by TGF-β1 knockdown.
Limitations
Single primary cell type in culture with no in-vivo bone measurements, despite the osteoporosis framing of the title.
Study record
| Study model | Cell study (in vitro) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | rat |
| System studied | Rat bone marrow mesenchymal stem cells under osteogenic differentiation |
| Population | Not reported |
| Design | Cell culture experiments |
| Sample size as reported | Not reported |
| Control group | untreated BMSCs; TGF-β1 knockdown |
| Route (data field only) | in-culture |
| Endpoints measured | osteogenic genes (ALP, Bglap, Runx2); calcified nodule formation; TGF-β/Smad pathway genes |
| Pathways measured | TGF-β / SMAD |
| Research areas | Bone |
| Evidence tier | D — Cell, tissue or analytical |
| Publication types | Journal Article |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Cellular
- Sample size
- n/a
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Weak
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.